LXRX
HEALTHCARELexicon Pharmaceuticals Inc
AI Insight
What's Moving LXRX Today?
No stock-specific AI insight has been generated for LXRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.77$2.53
$2.16
Fundamentals
Market Cap$955M
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE-16.0%
Profit Margin-37.5%
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding444.2M
LXRX News
25 articles- Lexicon Pharmaceuticals Stock - Sunday background on strategy and trialsAD HOC NEWS·Jun 21, 2026
- Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?Yahoo Finance·Jun 11, 2026
- Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?Motley Fool·Jun 11, 2026
- How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesYahoo Finance·Jun 4, 2026
- Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsYahoo Finance·Jun 3, 2026
- Lexicon (LXRX) Q1 2026 Earnings TranscriptMotley Fool·Jun 1, 2026
- Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)Yahoo Finance·May 22, 2026
- Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's ChangedYahoo Finance·May 13, 2026
- Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceYahoo Finance·May 12, 2026
- Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk MilestonesInsider Monkey·May 10, 2026
- 5 Best Fast Growing Penny Stocks to Buy Right NowInsider Monkey·May 9, 2026
- Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common sharesStock Titan·May 9, 2026
- [SCHEDULE 13D/A] LEXICON PHARMACEUTICALS, INC. Amended Major Shareholder ReportStock Titan·May 9, 2026
- Lexicon Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Earnings call transcript: Lexicon Pharmaceuticals Q1 2026 sees dramatic revenue surgeInvesting.com Canada·May 7, 2026
- Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1Yahoo Finance·May 7, 2026
- Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesYahoo Finance·May 7, 2026
- Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalYahoo Finance·May 4, 2026
- Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 TrialYahoo Finance·May 3, 2026
- Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851Yahoo Finance·May 1, 2026
- Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851Yahoo Finance·Apr 27, 2026
- Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin DataYahoo Finance·Apr 23, 2026
- Lexicon to Present Data at the American Academy of Neurology (AAN) Annual MeetingGlobeNewswire Inc.·Apr 17, 2026
All 25 articles loaded
Price Data
Open$2.10
Previous Close$2.16
Day High$2.24
Day Low$2.06
52 Week High$2.53
52 Week Low$0.77
52-Week Range
$0.77$2.53
$2.16
Fundamentals
Market Cap$955M
P/E Ratio—
EPS$-0.07
Dividend Yield—
Dividend / Share—
ROE-16.0%
Profit Margin-37.5%
Debt / Equity—
Trading
Volume2.8M
Avg Volume (10D)—
Shares Outstanding444.2M
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—